| abstract |
The present invention is a method of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, wherein X4P-001 is administered to reduce angiogenesis escape that commonly occurs with TKI therapy. Related to the method. The method demonstrates surprising results including regression of tumor size and cell number with relatively low toxicity. The present invention relates to a method for treating cancer, in particular to overcoming resistance to treatment with VEGF-R antagonists in cancers such as renal cell carcinoma. |